The interplay between angiogenesis and cervical cancer: a comprehensive review.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-05-05 DOI:10.1080/14737140.2025.2501073

Addrita Nandi, Arabinda Ghosh, Samir Kumar Sil

{"title":"The interplay between angiogenesis and cervical cancer: a comprehensive review.","authors":"Addrita Nandi, Arabinda Ghosh, Samir Kumar Sil","doi":"10.1080/14737140.2025.2501073","DOIUrl":null,"url":null,"abstract":"Introduction: Cervical cancer is still a major global health threat, specifically in countries with little access to health services. Angiogenesis in cervical cancer not only contributes to tumor growth, metastasis, and resistance to therapy but also serves as a therapeutic target itself. This gives hope for the possible therapy.Areas covered: This review covers key molecular mechanisms in cervical cancer, including VEGF/VEGFR, HIF-1α, and PI3K/Akt pathways. It also discusses anti-angiogenic therapies like bevacizumab, small-molecule compounds, and emerging approaches such as nanoparticle-based drug delivery. Emphasis is placed on angiogenesis-related biomarkers for diagnosis and treatment selection, stressing the need for affordable therapies in low-resource settings. A literature search was conducted using PubMed, Scopus, and Google Scholar up to March 2025, focusing on VEGF/VEGFR signaling, anti-angiogenic therapies, and resistance mechanisms in cervical cancer.Expert opinion: Despite promise, resistance, toxicity, and cost remain major challenges for anti-angiogenic therapy's clinical use. Combination strategies with immunotherapy, chemotherapy, and targeted agents may be more effective. Precision medicine using multi-omics and AI offers hope for better outcomes. Future studies should evaluate drug combinations with synergistic effects and develop management strategies to universalize innovative treatments.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2501073","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cervical cancer is still a major global health threat, specifically in countries with little access to health services. Angiogenesis in cervical cancer not only contributes to tumor growth, metastasis, and resistance to therapy but also serves as a therapeutic target itself. This gives hope for the possible therapy.

Areas covered: This review covers key molecular mechanisms in cervical cancer, including VEGF/VEGFR, HIF-1α, and PI3K/Akt pathways. It also discusses anti-angiogenic therapies like bevacizumab, small-molecule compounds, and emerging approaches such as nanoparticle-based drug delivery. Emphasis is placed on angiogenesis-related biomarkers for diagnosis and treatment selection, stressing the need for affordable therapies in low-resource settings. A literature search was conducted using PubMed, Scopus, and Google Scholar up to March 2025, focusing on VEGF/VEGFR signaling, anti-angiogenic therapies, and resistance mechanisms in cervical cancer.

Expert opinion: Despite promise, resistance, toxicity, and cost remain major challenges for anti-angiogenic therapy's clinical use. Combination strategies with immunotherapy, chemotherapy, and targeted agents may be more effective. Precision medicine using multi-omics and AI offers hope for better outcomes. Future studies should evaluate drug combinations with synergistic effects and develop management strategies to universalize innovative treatments.

查看原文本刊更多论文

血管生成与宫颈癌之间的相互作用：一个全面的综述。

引言：宫颈癌仍然是全球主要的健康威胁，特别是在难以获得保健服务的国家。宫颈癌中的血管生成不仅有助于肿瘤的生长、转移和对治疗的抵抗，而且本身也是治疗的靶点。这给可能的治疗带来了希望。涉及领域：本文综述了宫颈癌的关键分子机制，包括VEGF/VEGFR、HIF-1α和PI3K/Akt通路。它还讨论了抗血管生成疗法，如贝伐单抗，小分子化合物，以及新兴的方法，如纳米颗粒为基础的药物输送。重点放在血管生成相关的生物标志物的诊断和治疗选择，强调需要负担得起的治疗在低资源设置。截至2025年3月，我们使用PubMed、Scopus和谷歌Scholar进行文献检索，重点关注宫颈癌中VEGF/VEGFR信号、抗血管生成治疗和耐药机制。专家意见：尽管前景看好，但耐药性、毒性和成本仍然是抗血管生成疗法临床应用的主要挑战。联合免疫治疗、化疗和靶向药物可能更有效。使用多组学和人工智能的精准医疗为更好的结果带来了希望。未来的研究应评估协同作用的药物组合，并制定管理策略以推广创新治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.